The stock of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) is a huge mover today! About 407,287 shares traded hands or 68.76% up from the average. Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) has declined 21.19% since April 18, 2016 and is downtrending. It has underperformed by 25.62% the S&P500.
The move comes after 7 months negative chart setup for the $89.17M company. It was reported on Nov, 18 by Barchart.com. We have $3.26 PT which if reached, will make NASDAQ:DRNA worth $12.48 million less.
Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) Ratings Coverage
Out of 4 analysts covering Dicerna Pharmaceuticals (NASDAQ:DRNA), 3 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. Dicerna Pharmaceuticals has been the topic of 10 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The stock of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) earned “Outperform” rating by Cowen & Co on Tuesday, September 8. As per Thursday, June 30, the company rating was maintained by Stifel Nicolaus. The stock has “Buy” rating given by Stifel Nicolaus on Monday, August 10. Stifel Nicolaus maintained the shares of DRNA in a report on Tuesday, May 10 with “Buy” rating. The rating was maintained by Chardan Capital Markets with “Neutral” on Thursday, June 30. Stifel Nicolaus maintained the stock with “Buy” rating in Wednesday, November 11 report. The firm has “Neutral” rating by Chardan Capital Markets given on Monday, August 15.
According to Zacks Investment Research, “Dicerna Pharmaceuticals, Inc. is focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers. The company uses its proprietary RNA interference technology platform primarily in the United States and internationally. Dicerna Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts.”
Insitutional Activity: The institutional sentiment decreased to 0.56 in 2016 Q2. Its down 0.20, from 0.76 in 2016Q1. The ratio dived, as 15 funds sold all Dicerna Pharmaceuticals Inc shares owned while 18 reduced positions. 11 funds bought stakes while 14 increased positions. They now own 12.70 million shares or 13.90% less from 14.75 million shares in 2016Q1.
Barclays Public Lc accumulated 0% or 1,842 shares. Moreover, Millennium Mngmt Ltd Liability Com has 0% invested in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) for 52,693 shares. Bourgeon Capital Limited Liability Co holds 20,000 shares or 0.04% of its portfolio. Geode Cap Ltd Co, a Massachusetts-based fund reported 85,136 shares. The New Jersey-based Jacobs Levy Equity Management Inc has invested 0.01% in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA). The Massachusetts-based Eventide Asset Management Limited Company has invested 0.07% in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA). Art Advisors Ltd Liability Co accumulated 56,763 shares or 0.01% of the stock. Blackrock Limited Liability Corporation, a Delaware-based fund reported 2,670 shares. Connor Clark And Lunn Investment Limited has 20,400 shares for 0% of their US portfolio. Dafna Cap Ltd, a California-based fund reported 119,300 shares. Abingworth Limited Liability Partnership last reported 945,757 shares in the company. Proshare Advisors Ltd Liability last reported 0% of its portfolio in the stock. Financial Bank Of Montreal Can accumulated 0% or 24,609 shares. Twin Focus Cap Partners Ltd Liability, a Massachusetts-based fund reported 10,000 shares. Citigroup accumulated 3,569 shares or 0% of the stock.
Insider Transactions: Since November 14, 2016, the stock had 1 buy, and 1 sale for $38,987 net activity. $122,643 worth of shares were bought by FAMBROUGH DOUGLAS on Monday, November 14. 23,766 shares were sold by LANGER DENNIS, worth $83,656.
Another recent and important Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) news was published by Businesswire.com which published an article titled: “Dicerna Pharmaceuticals Appoints John â€œJackâ€ Green Interim Chief Financial Officer” on December 15, 2015.
DRNA Company Profile
Dicerna Pharmaceuticals, Inc., incorporated on October 24, 2006, is a ribonucleic acid (RNA) interference biopharmaceutical company. The Firm operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Firm is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. The Firm uses its RNAi technology platform to build a pipeline in these therapeutic areas.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.